Avarieux
back to explore
Septerna Inc logo

SEPN

Septerna Inc
NASDAQ NMS - GLOBAL MARKET· Pharmaceuticals· US· IPO 2024-10-25
$37.50
-0.18 (-0.48%)
last quote
Want the full multi-source brief on SEPN?
The agent pulls regulatory filings, news flow, prediction-market pricing, and macro context — then synthesizes what's not yet in the price.
open in agent
Today
Open
$37.50
High
$38.86
Low
$37.24
Previous close
$37.68
Fundamentals
Market cap
$2.11B
P/E (TTM)
—
P/S (TTM)
29.16x
P/B
3.27x
Gross margin
—
Operating margin
-77.07%
Net margin
-49.88%
Rev growth (YoY)
11790.11%
EPS growth (YoY)
—
ROE
-9.44%
52W high
$51.10
52W low
$11.98
Beta
0.79x
Industry peers
by market cap
TRLV-0.43%KARD+11.84%ETON+2.53%ANIP+1.59%PAHC+4.37%LBRX+5.05%AVLN+0.85%VRNO.NE
Upcoming earnings
next 30 days
2026-11-09in 66 days
Q3 2026EPS est $-0.48Rev est $20.2M
Recent SEC filings
CIK 1984086filing-language history →
8-K2026-08-25reports 2026-08-22
151 KB
42026-08-14reports 2026-08-12
18 KB
SCHEDULE 13D/A2026-08-14
16 KB
42026-08-14reports 2026-08-12
14 KB
SCHEDULE 13G/A2026-08-14
8 KB
42026-08-13reports 2026-08-11
12 KB
Recent news
2026-08-27 → 2026-09-03
SeekingAlpha · 5d
Septerna: GPCR Programs May Be Experimental, But I'm Holding For The Long Term
Septerna, Inc. has surged >315% since May 2025, driven by its GPCR-focused drug discovery and a high-profile collaboration with Novo Nordisk. Click for more.
SEC EDGAR Yahoo Finance TradingView Company website
This is the free preview

The agent layer adds regulatory-language drift detection, cross-venue prediction-market signals, macro overlays, programmable alert rules, overnight briefs, and a grounding verifier on every claim. 7-day Pro trial, no card required.

Start the trial